Jamison Private Wealth Management Inc. Buys 1,521 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Jamison Private Wealth Management Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,957 shares of the biopharmaceutical company’s stock after acquiring an additional 1,521 shares during the quarter. Jamison Private Wealth Management Inc.’s holdings in Gilead Sciences were worth $2,582,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. nVerses Capital LLC bought a new position in Gilead Sciences in the 3rd quarter valued at $25,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at $29,000. Valued Wealth Advisors LLC grew its position in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the 2nd quarter worth about $33,000. Finally, Friedenthal Financial purchased a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $50,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock valued at $42,130,461 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

NASDAQ GILD opened at $93.07 on Friday. The firm has a market capitalization of $115.99 billion, a PE ratio of 1,034.11, a P/E/G ratio of 1.31 and a beta of 0.18. The stock’s 50 day moving average is $91.74 and its 200 day moving average is $84.86. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the firm earned $2.29 EPS. The company’s revenue was up 7.0% compared to the same quarter last year. Research analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on GILD shares. Truist Financial upped their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. UBS Group raised their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.